Abstract
To determine if the chemotherapy resistance of non-small cell lung cancer could be modified by oral verapamil, 72 patients were entered into a randomised trial of verapamil plus chemotherapy vs the same chemotherapy alone. Verapamil 480 mg day-1 was given for 3 days starting 24 h prior to chemotherapy which consisted of bolus vindesine 7 mg followed by ifosfamide/mesna 5 g m-2 over 24 h, followed by mesna alone for a further 8 h. Cycles were repeated every 3 weeks for up to six courses. Sixty-six patients were eligible for tumour response analysis and responses occurred in 41% of those randomised to chemotherapy plus verapamil and in 18% of those randomised to chemotherapy alone (P = 0.057). Median survival from start of treatment was significantly better in the verapamil arm (P = 0.02). Toxicity of the combination of chemotherapy plus verapamil was principally neurological and was manageable. Thus the addition of oral verapamil to vindesine/ifosfamide chemotherapy is feasible and in this study was associated with improved outcome. Further confirmation of these observations is required in non-small cell lung cancer, a tumour characterised by resistance to conventional chemotherapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Millward, M., Cantwell, B., Munro, N. et al. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer 67, 1031–1035 (1993). https://doi.org/10.1038/bjc.1993.189
Issue Date:
DOI: https://doi.org/10.1038/bjc.1993.189
This article is cited by
Role of ion channels in regulating Ca2+ homeostasis during the interplay between immune and cancer cells
Cell Death & Disease (2015)
Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases
Inflammation Research (2015)
Priming cancer cells for drug resistance: role of the fibroblast niche
Frontiers in Biology (2014)
Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?
Cancer and Metastasis Reviews (2013)